Site icon pharmaceutical daily

Shattuck Labs Announces Participation in Upcoming 11th Annual SVB Leerink Global Healthcare Conference

AUSTIN, TX and DURHAM, NC, Feb. 09, 2022 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced that company management will participate in the 11th Annual SVB Leerink Global Healthcare Conference being held February 14-18, 2022.   Presentation Details Conference: 11th Annual SVB Leerink Global Healthcare Conference Format: Corporate Presentation Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer Date: February 18, 2022 Time: 10:40 a.m. EST A live webcast of the presentation will be available on the Events & Presentations section of the Company’s website. A replay of the webcasts will be archived for up to 90 days following the presentation date. About Shattuck Labs, Inc. Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in two Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com. Investor Contact: Conor Richardson Senior Director, Finance & Investor Relations Shattuck Labs, Inc. InvestorRelations@shattucklabs.com Media Contact: Stephanie Ascher Managing Director Stern Investor Relations, Inc. Stephanie.ascher@sternir.com

Exit mobile version